CBER Overview of Laboratory of Molecular Virology Indira Hewlett, Ph.D Laboratory Chief.

Slides:

Advertisements

Similar presentations

Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.

Advertisements

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.

Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.

Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.

Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

MEDICAL MICROBIOLOGY w WHAT IS MEDICAL MICROBIOLOGY? w WHO STUDIES MEDICAL MICRO? w WHY DO WE STUDY IT? w WHERE DO WE STUDY IT? w WHAT KNOWLEDGE WILL.

Overview of the Division of Viral Products

Virology Program Program Head: Mel Krajden, Martin Petric Section Head: Annie Mak,Peggy Tsang VS Staff: 40 Research:  SARS  Influenza viruses  Gastroenteritis.

Overview of the Division of Viral Products VRBPAC Presentation of the Site Visit Report for the Laboratories of Retrovirus Research, Immunoregulation,

An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

FDA/CBER Role in Smallpox Vaccine Safety Bob Ball, MD, MPH, ScM Chief, Vaccine Safety Branch Office of Biostatistics and Epidemiology CBER, FDA January.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

Special Topics in IND Regulation

1 Overview: Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular,

Malaria Research Program at CBER Studies to improve Blood Safety from the risk of transfusion- transmitted malaria, and malaria pathogenesis and control.

CBER's policies on assay regulation: Definitions of assay performance characteristics Andrew I. Dayton, M.D., Ph.D. CBER.

CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.

Requirements for Premarket Submissions: In vitro Diagnostic Instrumentation and Software Related to Donor Screening and HIV Diagnostic Assay Systems Diane.

Association of Public Health Laboratories National Center for Public Health Laboratory Leadership Cohort IV.

Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.

Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.

Update on CBER HIV NAT panels and International panels Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology DETTD/OBRR/FDA May 28, 2009 XXI SoGAT meeting.

Xenotropic Murine Leukemia Virus Related Virus (XMRV) Informational Presentation BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of.

Ensuring Product Quality in Gene Transfer Clinical Trials

CBER CBER 510(k) Issues Sheryl A. Kochman, MT(ASCP) Chief, Devices Review Branch DBA/OBRR/CBER IVD Roundtable – OIVD Workshop April 23, 2003.

IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.

Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

CBER HCT/P Contamination Prevention and Biologic Product Sterility Regulations Applicable to PBSCs Cell Therapy Liaison Meeting June 16, 2006 Ellen F.

HIV variants and US licensed assays Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology CBER/FDA XIX SOGAT, 2006.

Regulatory Big Brother of Biotechnology. Role of FDA FDA was designed to promote and protect the public’s health Food and Drug Cosmetic Act first passed.

Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.

An Update on FDA/OBRR XMRV activities BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of Molecular Virology DETTD/CBER/FDA.

1 Overview of the Laboratory of Hepatitis Viruses March 20, 2014 VRBPAC Discussion of the December 5, 2013 Site Visit for the Laboratory of Hepatitis Viruses.

Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.

West Nile Virus: Pathogenesis and Diagnostic Tools Maria Rios, PhD - Senior Staff Fellow Laboratory of Molecular Virology DETTD/OBRR/CBER/FDA WNV epidemic.

E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.

Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.

1 Laboratory of Bacterial, Parasitic and Unconventional Agents (LBPUA) Research Programs Report to BPAC 13 July 2006 Site Visit by Ad Hoc Review Committee.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

FDA’s Critical Path Research Initiative & Intro to the CBER Research Program Kathryn M. Carbone, M.D. Associate Director for Research CBER/FDA.

A. Discovery of New Genes related to Leishmania Pathogenesis and as Biomarkers of Attenuation Using a Genomic Microarray B. Multiplex PCR Microarray Assay.

Laboratory of Immunobiochemistry Ronald L. Rabin, MD Allergenic Products Advisory Committee 18 March 2009.

OBRR Response to BPAC Recommendations on the Office Research Program Office Site Visit: July 22, 2005 BPAC Recommendations: February 10, 2006 C.D. Atreya,

Office of Blood Research and Review Overview of Research Jay S. Epstein, M.D. Director, OBRR, CBER Blood Products Advisory Committee Meeting March 10,

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Office of Vaccines Research and Review

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,

Introduction to FDA’s Office of Vaccines Research and Review Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review.

Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.

Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,

Overview Laboratory of Bacterial Polysaccharides From cover - Science, 23 March, 2001.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

CATHERINA JEMMOTT NOVEMBER 26TH, health districts 7 district health teams 52 health centre/clinics 2 district hospitals Main hospital in Roseau.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Specialties and your career. Starting work in a lab When you apply for your first job in a laboratory it will be in a specific discipline: haematology.

West Nile Virus (WNV) and Donors of Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps) Melissa A. Greenwald, MD Division of Human Tissues.

Proposed Animal Study to Evaluate Simian Foamy Virus (SFV) Transmission by Blood Arifa S. Khan, Ph.D. DVP, OVRR, CBER, FDA BPAC, December 13, 2001.

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

Chief, Laboratory of Molecular Virology, CBER, FDA

Update on CBER HIV-1 Subtype panel

Presentation transcript:

CBER Overview of Laboratory of Molecular Virology Indira Hewlett, Ph.D Laboratory Chief

CBER CBER-OBRR DIVISION OF EMERGING& TRANSFUSION TRANSMITTED DISEASES Director Hira L. Nakhasi, Ph.D. Deputy Director Paul A. Mied, Ph.D. Product Testing staff Robin M. Biswas, M.D. Laboratory of Bacterial, Parasitic, &Unconventional agents David Asher, M.D. Laboratory of Molecular Virology Indira K. Hewlett, Ph.D. Laboratory of Hepatitis & Related Emerging Agents Gerardo Kaplan, Ph.D.

CBER LMV - History l Created during CBER reorganization of 1992 l Responsible for all HIV tests based on synthetic peptides, rDNA and molecular probes l Acquired responsibility for all HIV and HTLV products in 1999 l WNV, Vaccinia virus and software added since 2001

CBER Laboratory of Molecular Virology Indira Hewlett, Chief Hewlett Lab Lee, S Wood, O Tang, S Srinivasan, K (Counter- terrorism Dayton Lab Zhang, M Khan, Q Dhawan Lab Devadas, K ORISE Rios Lab Daniel, S Grinev, A Regulatory Product Akolkar, P Geyer, S Hu, J Software Gubernot, D Sanchez, B

CBER LMV mission- Regulatory l Review and license applications for a) in vitro tests (donor screening and diagnostic) for HIV, HTLV and other retroviruses in blood, plasma and other body fluids e.g. oral fluid b) WNV donor screening assays since 2003 c) consult reviews for Smallpox submissions d) software and instrument reviews for DETTD

CBER LMV mission- Regulatory (con’t ) l Conventional Ab, Ag and NAT assays, rapid tests for diagnosis, patient monitoring, genotyping, drug resistance, and home use l Perform inspections of test kit manufacturing facilities l Develop guidelines, review criteria and standards for validation of tests l Develop policies related to their use through interagency/industry and BPAC discussions

CBER LMV mission: Research l Perform research on HIV-1, HIV-2, HTLV, WNV and Vaccinia l Conduct laboratory investigations of disease transmission and pathogenesis l Develop and evaluate new technologies and methods to ensure blood safety from transmission of HIV, WNV and Vaccinia l Develop laboratory standards/panels for standardization and lot release of HIV and WNV assays

CBER Research programs Hewlett: HIV diagnosis and pathogenesis -Genetic diversity, diagnostic significance and pathogenesis of HIV variants -Reference reagents for HIV NAT assays Srinivasan: Vaccinia virus as a model for Smallpox -Viremia in vaccinated individuals -Molecular basis for myocarditis

CBER

CBER Summary l LMV has maintained product responsibility for HIV tests for over a decade l New product responsibilities including WNV, Vaccinia, software/instruments l LMV has maintained and initiated new research programs to support its regulatory function